Comprehensive Stock Comparison
Compare Syra Health Corp. Class A Common Stock (SYRA) vs Tenet Healthcare Corporation (THC) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SYRA | 44.7% revenue growth vs THC's 3.1% |
| Quality / Margins | THC | 6.6% net margin vs SYRA's -16.9% |
| Stability / Safety | SYRA | Beta 0.78 vs THC's 0.93, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | THC | +89.1% vs SYRA's -75.3% |
| Efficiency (ROA) | THC | 4.7% ROA vs SYRA's -38.8%, ROIC 13.5% vs -294.7% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Syra Health is a healthcare services company that provides health education, population health management, behavioral health, workforce solutions, and digital health services. It generates revenue through service contracts with government agencies, health networks, and pharmaceutical manufacturers — primarily from its health education and population health management segments. The company's competitive advantage lies in its integrated service portfolio addressing multiple healthcare system pain points, including its Syrenity telehealth platform for mental health services.
Tenet Healthcare is a diversified healthcare services company that operates hospitals, ambulatory surgery centers, and urgent care facilities. It generates revenue primarily from hospital operations (acute care services) and ambulatory care centers, with additional income from its Conifer segment providing revenue cycle management services to other healthcare providers. The company's scale and integrated network of facilities across multiple states create operational efficiencies and referral pathways that serve as its competitive advantage.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
THC leads in 3 of 6 categories (Financial Metrics, Profitability & Efficiency). SYRA leads in 1 (Valuation Metrics). 1 tied.
Financial Metrics (TTM)
THC is the larger business by revenue, generating $21.3B annually — 2841.8x SYRA's $7M. THC is the more profitable business, keeping 6.6% of every revenue dollar as net income compared to SYRA's -16.9%. On growth, THC holds the edge at +9.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SYRASyra Health Corp.… | THCTenet Healthcare … |
|---|---|---|
| RevenueTrailing 12 months | $7M | $21.3B |
| EBITDAEarnings before interest/tax | -$1M | $4.4B |
| Net IncomeAfter-tax profit | -$1M | $1.4B |
| Free Cash FlowCash after capex | -$231,031 | $2.5B |
| Gross MarginGross profit ÷ Revenue | +31.4% | +55.9% |
| Operating MarginEBIT ÷ Revenue | -16.9% | +16.5% |
| Net MarginNet income ÷ Revenue | -16.9% | +6.6% |
| FCF MarginFCF ÷ Revenue | -3.1% | +11.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.1% | +9.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +67.1% | +27.1% |
Valuation Metrics
| Metric | SYRASyra Health Corp.… | THCTenet Healthcare … |
|---|---|---|
| Market CapShares × price | $60,000 | $21.0B |
| Enterprise ValueMkt cap + debt − cash | -$2M | $31.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.19x | 15.45x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 14.12x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.47x |
| EV / EBITDAEnterprise value multiple | — | 7.17x |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 0.99x |
| Price / BookPrice ÷ Book value/share | 0.25x | 2.42x |
| Price / FCFMarket cap ÷ FCF | — | 8.32x |
Profitability & Efficiency
THC delivers a 15.7% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-57 for SYRA. SYRA carries lower financial leverage with a 0.16x debt-to-equity ratio, signaling a more conservative balance sheet compared to THC's 1.47x. On the Piotroski fundamental quality scale (0–9), THC scores 7/9 vs SYRA's 3/9, reflecting strong financial health.
| Metric | SYRASyra Health Corp.… | THCTenet Healthcare … |
|---|---|---|
| ROE (TTM)Return on equity | -57.3% | +15.7% |
| ROA (TTM)Return on assets | -38.8% | +4.7% |
| ROICReturn on invested capital | -2.9% | +13.5% |
| ROCEReturn on capital employed | -106.4% | +14.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.16x | 1.47x |
| Net DebtTotal debt minus cash | -$2M | $10.3B |
| Cash & Equiv.Liquid assets | $2M | $2.9B |
| Total DebtShort + long-term debt | $452,077 | $13.2B |
| Interest CoverageEBIT ÷ Interest expense | -99.37x | 5.85x |
Total Returns (with DRIP)
A $10,000 investment in THC five years ago would be worth $45,270 today (with dividends reinvested), compared to $333 for SYRA. Over the past 12 months, THC leads with a +89.1% total return vs SYRA's -75.3%. The 3-year compound annual growth rate (CAGR) favors THC at 59.9% vs SYRA's -67.8% — a key indicator of consistent wealth creation.
| Metric | SYRASyra Health Corp.… | THCTenet Healthcare … |
|---|---|---|
| YTD ReturnYear-to-date | +14.9% | +20.0% |
| 1-Year ReturnPast 12 months | -75.3% | +89.1% |
| 3-Year ReturnCumulative with dividends | -96.7% | +309.0% |
| 5-Year ReturnCumulative with dividends | -96.7% | +352.7% |
| 10-Year ReturnCumulative with dividends | -96.7% | +864.5% |
| CAGR (3Y)Annualised 3-year return | -67.8% | +59.9% |
Risk & Volatility
SYRA is the less volatile stock with a 0.78 beta — it tends to amplify market swings less than THC's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. THC currently trades 99.5% from its 52-week high vs SYRA's 24.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SYRASyra Health Corp.… | THCTenet Healthcare … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 0.93x |
| 52-Week HighHighest price in past year | $0.41 | $240.57 |
| 52-Week LowLowest price in past year | $0.03 | $109.82 |
| % of 52W HighCurrent price vs 52-week peak | +24.4% | +99.5% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 74.5 |
| Avg Volume (50D)Average daily shares traded | 12K | 826K |
Analyst Outlook
| Metric | SYRASyra Health Corp.… | THCTenet Healthcare … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $257.45 |
| # AnalystsCovering analysts | — | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +6.8% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Sep 23 | Feb 26 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | 100 | 2.67 | -97.3% |
| Tenet Healthcare Co… (THC) | 100 | 284.16 | +184.2% |
Tenet Healthcare Co… (THC) returned +353% over 5 years vs Syra Health Corp. C… (SYRA)'s -97%. A $10,000 investment in THC 5 years ago would be worth $45,270 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | $0.00 | $8M | — |
| Tenet Healthcare Co… (THC) | $19.6B | $21.3B | +8.6% |
Tenet Healthcare Corporation's revenue grew from $19.6B (2016) to $21.3B (2025) — a 0.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | -0.2% | -47.1% | -20147.6% |
| Tenet Healthcare Co… (THC) | -1.0% | 6.6% | +774.8% |
Tenet Healthcare Corporation's net margin went from -1% (2016) to 7% (2025).
Chart 4P/E Ratio History — 7 Years
| Stock | 2018 | 2025 | Change |
|---|---|---|---|
| Tenet Healthcare Co… (THC) | 16 | 12.8 | -20.0% |
Tenet Healthcare Corporation has traded in a 4x–16x P/E range over 7 years; current trailing P/E is ~15x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Syra Health Corp. C… (SYRA) | -0 | -0.52 | -74185.7% |
| Tenet Healthcare Co… (THC) | -1.93 | 15.49 | +902.6% |
Tenet Healthcare Corporation's EPS grew from $-1.93 (2016) to $15.49 (2025).
Chart 6Free Cash Flow — 5 Years
Syra Health Corp. Class A Common Stock generated $-3M FCF in 2024 (-3015% vs 2021). Tenet Healthcare Corporation generated $3B FCF in 2025 (+178% vs 2021).
SYRA vs THC: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is SYRA or THC a better buy right now?
Tenet Healthcare Corporation (THC) offers the better valuation at 15.5x trailing P/E (14.1x forward), making it the more compelling value choice. Analysts rate Tenet Healthcare Corporation (THC) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — SYRA or THC?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +352.7%, compared to -96.7% for Syra Health Corp. Class A Common Stock (SYRA). A $10,000 investment in THC five years ago would be worth approximately $45K today (assuming dividends reinvested). Over 10 years, the gap is even starker: THC returned +864.5% versus SYRA's -96.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — SYRA or THC?
By beta (market sensitivity over 5 years), Syra Health Corp. Class A Common Stock (SYRA) is the lower-risk stock at 0.78β versus Tenet Healthcare Corporation's 0.93β — meaning THC is approximately 19% more volatile than SYRA relative to the S&P 500. On balance sheet safety, Syra Health Corp. Class A Common Stock (SYRA) carries a lower debt/equity ratio of 16% versus 147% for Tenet Healthcare Corporation — giving it more financial flexibility in a downturn.
04Which has better profit margins — SYRA or THC?
Tenet Healthcare Corporation (THC) is the more profitable company, earning 6.6% net margin versus -47.1% for Syra Health Corp. Class A Common Stock — meaning it keeps 6.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16.5% versus -47.2% for SYRA. At the gross margin level — before operating expenses — THC leads at 41.4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — SYRA or THC?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is SYRA or THC better for a retirement portfolio?
For long-horizon retirement investors, Tenet Healthcare Corporation (THC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.93), +864.5% 10Y return). Both have compounded well over 10 years (THC: +864.5%, SYRA: -96.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between SYRA and THC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: SYRA is a small-cap quality compounder stock; THC is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.